Xiangyu Liu

4PUBLICATIONS
36CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 24, 2026
Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer.

|Feb 11, 2026
Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.

Minjiang Chen, Iurie Bulat, Marina Maglakelidze

|Feb 12, 2025
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies.

Oleg Demin, Ying Ou, Galina Kolesova

|Mar 22, 2024
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.

Tian Yu, Xiangyu Liu, Chi-Yuan Wu

Pageof 1

Frequent Collaborators

3 joint publications

Tian Yu

3 joint publications

Nageshwar Budha

1 joint publications

Chi-Yuan Wu

1 joint publications

Zhiyu Tang